Print

Pluristem Therapeutics (PSTI) Receives Approval to Commence a Phase I/II Study for Muscle Regeneration in Germany  
8/7/2012 9:45:46 AM

HAIFA, Israel, Aug. 7, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has received approval from the Paul-Ehrlich-Institute (PEI), the medical regulatory body in Germany, to commence a Phase I/II randomized, double blind, placebo controlled study to assess the safety and efficacy of its PLX cells, through intramuscular injections, for the regeneration of injured gluteal musculature following total hip replacement.
//-->